Paper19620385
Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
Wang DD and 4 others. J Clin Pharmacol, 2009. Cited by 153 papers, by iCite.
Cite this record
ConductScience Library. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. Papers, record 19620385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19620385
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Models, Biological | Major topic |
| Adult | |
| Body Surface Area | |
| Body Weight | |
| Clinical Trials as Topic | |
| Computer Simulation | |
| Dose-Response Relationship, Drug | |
| Humans |
Source PubMed
Trials5
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04062708 | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer | Background | ClinicalTrials.gov | |
| NCT04441138 | Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC | Background | ClinicalTrials.gov | |
| NCT04765709 | Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC | Background | ClinicalTrials.gov | |
| NCT05568212 | Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab | Background | ClinicalTrials.gov | |
| NCT07146230 | The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 | Background | ClinicalTrials.gov |
Cited by93
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 153 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42742477 | Population Pharmacokinetics and Exposure-Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non-Muscle Invasive Bladder Cancer and Other Solid Tumors. | J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42742477 | PubMed |
| 42671472 | Body weight predicts denosumab pharmacodynamic duration: a real-world longitudinal cohort study. | Osteoporos Int | 2026 | https://conductscience.org/library/papers/42671472 | PubMed |
| 42469164 | Denecimig (Mim8) prophylaxis once every 2 weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER4. | Blood Adv | 2026 | https://conductscience.org/library/papers/42469164 | PubMed |
| 41824265 | Fixed Dosing of Leuprolide Acetate, a GnRH Agonist, in Children with Central Precocious Puberty: A Population Pharmacokinetic Justification. | Paediatr Drugs | 2026 | https://conductscience.org/library/papers/41824265 | PubMed |
| 41466592 | Optimizing Body Size-Based Dosing Approaches for Antibody-Drug Conjugates. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/41466592 | PubMed |
| 41321671 | Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41321671 | PubMed |
| 41310951 | Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All. | Arthritis Rheumatol | 2026 | https://conductscience.org/library/papers/41310951 | PubMed |
| 40920298 | Targeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation. | BioDrugs | 2025 | https://conductscience.org/library/papers/40920298 | PubMed |
| 40830740 | Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach. | Target Oncol | 2025 | https://conductscience.org/library/papers/40830740 | PubMed |
| 40817431 | Re-Evaluation of Fixed Dosing Versus Body Size-Based Dosing Approaches for Large Molecule Therapeutics in Adults. | Clin Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40817431 | PubMed |
| 40686031 | Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling of Serum M-Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma. | Clin Transl Sci | 2025 | https://conductscience.org/library/papers/40686031 | PubMed |
| 40667684 | Donanemab exposure-response in early symptomatic Alzheimer's disease. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/40667684 | PubMed |
| 40458046 | Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women. | J Antimicrob Chemother | 2025 | https://conductscience.org/library/papers/40458046 | PubMed |
| 40427101 | Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma? | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40427101 | PubMed |
| 40316348 | A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours. | BMJ Open | 2025 | https://conductscience.org/library/papers/40316348 | PubMed |
| 40308078 | Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response Analyses. | Clin Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40308078 | PubMed |
| 40000533 | Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma. | Target Oncol | 2025 | https://conductscience.org/library/papers/40000533 | PubMed |
| 39849218 | Pharmacokinetics of Nivolumab and Erythropoietin in a Rat Model of Diet-Induced Obesity. | Pharm Res | 2025 | https://conductscience.org/library/papers/39849218 | PubMed |
| 39375952 | Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor. | Cancer Sci | 2024 | https://conductscience.org/library/papers/39375952 | PubMed |
| 38711252 | Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive-stage small-cell lung cancer. | CPT Pharmacometrics Syst Pharmacol | 2024 | https://conductscience.org/library/papers/38711252 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19620385
GET https://conductscience.org/api/papers/v1/19620385/cited_by?page=2